A selective PDE4 inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Ro 20-1724

Item No. 18272

Technical Information
Formal Name
4-[(3-butoxy-4-methoxyphenyl)methyl]-2-imidazolidinone
CAS Number
29925-17-5
Synonyms
  • 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
Molecular Formula
C15H22N2O3
Formula Weight
Purity
≥95%
Formulation
A crystalline solid
DMF: 30 mg/mlDMF:PBS (pH 7.2) (1:1): 0.5 mg/mlDMSO: 25 mg/mlEthanol: 25 mg/ml
λmax
230, 280 nm
SMILES
COC1=C(OCCCC)C=C(CC2CNC(N2)=O)C=C1
InChi Code
InChI=1S/C15H22N2O3/c1-3-4-7-20-14-9-11(5-6-13(14)19-2)8-12-10-16-15(18)17-12/h5-6,9,12H,3-4,7-8,10H2,1-2H3,(H2,16,17,18)
InChi Key
PDMUULPVBYQBBK-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Product Description

    Ro 20-1724 is a cell-permeable, cAMP-specific phosphodiesterase type IV (PDE4) inhibitor (IC50 = 2 µM).1,2 It weakly inhibits PDE3 with a Ki value greater than 25 µM.1 Ro 20-1724 inhibits the release of cytokines and other inflammatory signals as well as prevents the development of reactive oxygen species.3 It is often used to study cAMP-related functions in vascular cells.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Reeves, M.L., Leigh, B.K., and England, P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J. 241, 535-541 (1987).

    2. Soderling, S.H., Bayuga, S.J., and Beavo, J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA 95, 8991-8996 (1998).

    3. Totani, L., Piccoli, A., Dell'Elba, G., et alPhosphodiesterases type-4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury. Arterioscler. Thromb. Vasc. Biol. 34(8), 1689-1696 (2014).

    4. Zhai, K., Hubert, F., Nicolas, V., et alβ-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells. PLoS One 7(10), 1-13 (2012).